Clinical Trial Update: Post Market Surveillance to Observe Safety of Prevenar13™ in Adults

View source ↗

Summary

This document reports the completion of a post-market safety surveillance study for Prevnar 13 in adults, with results posted in 2017. It provides observational…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease | Status: COMPLETED | Results posted: 2017-04-18